Design Therapeutics, Inc. (DSGN) Cash Flow Statement

The gap between net income and operating cash flow is primarily attributable to non-cash stock-based compensation, which averaged $3.5M per quarter, and working capital fluctuations. In 2024Q1, OCF/NI exceeded 1.0, indicating that cash burn outpaced the accounting loss, likely due to working capital outflows. This suggests that the reported net loss understates the true cash consumption, and investors should focus on cash burn rather than net income as the primary liquidity metric.

The quarterly FCF deficit has widened consistently, with the most recent quarter showing a burn of $15.5M, up from $9.9M in 2024Q4. This trajectory indicates that the company is accelerating its investment in clinical development, likely for the DT-216 program, without any offsetting revenue. Given the reported cash position of $16.9M, the current burn rate implies a runway of approximately one quarter, underscoring the urgency for additional financing.

With CapEx consistently below $0.2M per quarter, the company is not investing in significant fixed assets, which is typical for a preclinical biotech relying on outsourced manufacturing and CROs. This suggests that the primary cash consumption is R&D expenses, which have grown 69% since 2024Q1. The lack of capital intensity implies that the company's future cash needs will be driven by clinical trial costs and manufacturing scale-up, not infrastructure.

The quarterly working capital adjustments are relatively small compared to the overall burn, but they do cause quarter-to-quarter volatility in operating cash flow. For example, 2025Q3 saw a positive $2.9M working capital inflow, while 2026Q1 had a -$2.8M outflow, likely reflecting the timing of vendor payments and prepaid expenses. These swings are not indicative of operational efficiency but rather the lumpy nature of clinical trial expenditures.

The absence of capital returns is expected for a pre-revenue biotech, but it underscores that the company is entirely focused on advancing its pipeline. The only deployment of capital is operational, with R&D expenses consuming the majority of cash. Given the limited cash runway, investors should monitor whether management will need to raise capital through equity issuance, which could dilute existing shareholders.

The cumulative gap between net income and operating cash flow is primarily due to non-cash stock-based compensation, which totaled approximately $35M over the period. This indicates that the accounting losses overstate the actual cash consumption, but the company is still burning cash at a significant rate. The divergence suggests that while SBC is a non-cash expense, it represents real economic cost in the form of dilution, which investors should factor into their valuation.